BioRestorative Therapies (BRTX) Total Current Liabilities (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Total Current Liabilities came in at $3.7 million in Q4 2025, down 0.68% YoY from $3.7 million in Q4 2024, and up 8.36% on a QoQ basis from $3.4 million in Q3 2025.
BioRestorative Therapies (BRTX) Total Current Liabilities (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Total Current Liabilities data on file, last reported at $3.7 million in Q4 2025.
- Quarterly Total Current Liabilities fell 0.68% year-over-year to $3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.7 million (down 0.68% YoY) and the FY2025 annual result came in at $3.7 million, down 0.68% from the prior year.
- Total Current Liabilities advanced to $3.7 million in Q4 2025, from $3.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $14.7 million in Q1 2022 to a low of $363822.0 in Q4 2021.
- A 5-year average of $4.8 million and a median of $3.7 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities sank 92.99% — and 2022, when it surged 1544.22%.
- Tracing BRTX's Total Current Liabilities over 5 years: stood at $363822.0 in 2021, then surged by 1544.22% to $6.0 million in 2022, then tumbled by 56.41% to $2.6 million in 2023, then surged by 43.76% to $3.7 million in 2024, then dropped by 0.68% to $3.7 million in 2025.
- The last three Total Current Liabilities figures came in at $3.7 million (Q4 2025), $3.4 million (Q3 2025), and $3.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 3.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.44 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 3.75 Mn |
| Sep 30, 2024 | 4.58 Mn |
| Jun 30, 2024 | 5.32 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 10.57 Mn |
| Mar 31, 2023 | 7.50 Mn |
| Dec 31, 2022 | 5.98 Mn |
| Sep 30, 2022 | 7.94 Mn |
| Jun 30, 2022 | 7.05 Mn |
| Mar 31, 2022 | 14.70 Mn |
| Dec 31, 2021 | 363,822.00 |
| Sep 30, 2021 | 873,473.00 |
| Jun 30, 2021 | 1.33 Mn |
| Mar 31, 2021 | 1.29 Mn |